Stage 2C: Potential Benefits of Adjuvant Treatment
Without Adjuvant Treatment
Figure A: Stage 2C Melanoma: overall survival of Stage 2C melanoma patients without treatment
Figure A explanatory: The diagram above shows data for melanoma patients 5 years and 10 years after receiving a melanoma diagnosis. It is based on a study using a global; international melanoma database from ten countries (Eighth Edition International Melanoma Database)1 It shows how many patients are likely to survive (still be alive) 5 years and 10 years after receiving their melanoma diagnosis.
For 100 people diagnosed with Stage 2C melanoma who are treated with surgery alone (and do not have adjuvant therapy), we would expect 82 people to have had no further recurrence of their melanoma five years after surgery. This is 82% of individuals — shown in yellow.
After the same period (within five years of their surgery), eighteen people in the group will have needed more treatment for their melanoma. The melanoma will therefore have recurred (returned) in 18% of individuals — shown in purple.
At ten years after surgery, 75% of people are recurrence free, meaning the melanoma has returned in 25% of people.